WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances. by Jacobsson, Susanne et al.
LSHTM Research Online
Jacobsson, Susanne; Boiko, Iryna; Golparian, Daniel; Blondeel, Karel; Kiarie, James; Toskin, Igor;
Peeling, Rosanna W; Unemo, Magnus; (2018) WHO laboratory validation of Xpert((R)) CT/NG and
Xpert((R)) TV on the GeneXpert system verifies high performances. APMIS, 126 (12). pp. 907-912.
ISSN 0903-4641 DOI: https://doi.org/10.1111/apm.12902
Downloaded from: http://researchonline.lshtm.ac.uk/4652975/
DOI: https://doi.org/10.1111/apm.12902
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
WHO laboratory validation of Xpert CT/NG and
Xpert TV on the GeneXpert system verifies
high performances
SUSANNE JACOBSSON,1 IRYNA BOIKO,2 DANIEL GOLPARIAN,1 KAREL BLONDEEL,3
JAMES KIARIE,3 IGOR TOSKIN,3 ROSANNA W. PEELING4 and MAGNUS UNEMO1
1WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference
Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Faculty of Medicine
and Health, €Orebro University, €Orebro, Sweden; 2Clinical Laboratory Department, Ternopil Regional
Clinical Dermatovenerologic Dispensary, Ternopil, Ukraine; 3Department of Reproductive Health and
Research, World Health Organization (WHO), Geneva, Switzerland; and 4London School of Hygiene and
Tropical Medicine (LSHTM), London, UK
Jacobsson S, Boiko I, Golparian D, Blondeel K, Kiarie J, Toskin I, Peeling RW, Unemo M. WHO laboratory
validation of Xpert CT/NG and Xpert TV on the GeneXpert system veriﬁes high performances. APMIS
2018; 126: 907–912.
Eﬀective tests for diagnosis of sexually transmitted infections (STIs), used point of care to inform treatment and man-
agement decisions, are urgently needed. We evaluated the analytical sensitivity and speciﬁcity of the Xpert CT/NG
and Xpert TV tests, examining 339 samples spiked with phenotypically and/or genetically diverse strains of Neisseria
gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, and other related species that may cross-react. The
APTIMA Combo 2 test and APTIMA TV test were used as reference tests. The analytical sensitivity for all three
agents in the Xpert CT/NG and Xpert TV tests was ≤102 genome equivalents/reaction. The analytical speciﬁcity of
both tests was high. False-positive results were identiﬁed in the Xpert TV test when challenging with high concentra-
tions of Trichomonas tenax, Trichomonas gallinae, Trichomonas stableri, and Trichomonas aotus. However, the clinical
relevance of these cross-reactions can likely be neglected, because these species have not been identiﬁed in urogenital
samples from humans. In conclusion, the analytical sensitivity and speciﬁcity of the user-friendly Xpert CT/NG and
Xpert TV tests on the GeneXpert system were high. The results support the use of specimens from also extra-genital
sites, for example, pharynx and rectum. However, appropriate clinical validations are additionally required.
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The World Health Organization (WHO) estimated
in 2012 that Trichomonas vaginalis (TV) causes
~143 million cases of trichomoniasis in men and
women globally per year, Chlamydia trachomatis
(CT) ~131 million cases of chlamydia, and Neisseria
gonorrhoeae (NG) ~78 million cases of gonorrhea.
If these frequently asymptomatic STI cases are not
detected and treated, they might result in severe
complications and sequelae (1). In many settings
internationally, laboratory detection of these STIs
is suboptimal or totally absent.
Traditionally, laboratory diagnosis of these infec-
tions has mostly relied on microscopy and/or culture
(2, 3). During the last two decade(s), nucleic acid
ampliﬁcation tests (NAATs) have become the recom-
mended diagnostic methods, due to superior perfor-
mance characteristics (3). However, the NAATs are
technically challenging, laboratory based, and too
expensive for less-resourced settings (1). Point-of-
care tests (POCTs), providing results at the time of
the patient visit, would be exceedingly valuable inReceived 3 August 2018. Accepted 9 October 2018
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particularly less-resourced settings but also more-
resourced settings. POCTs enable early detection of
the speciﬁc STI agents and guide treatment, fore-
stalling development of sequelae and adverse events,
interrupting onward transmission, and oﬀering
opportunities for counseling and partner notiﬁca-
tion. An ideal POCT should fulﬁll the WHO
ASSURED criteria, namely be aﬀordable, sensitive,
speciﬁc, user-friendly, rapid and robust, equipment-
free, and deliverable to the end user (4). Simple,
rapid, and equipment-free POCTs for the diagnosis
of CT, NG, and TV infections are commercially
available; however, in general, these POCTs have a
suboptimal sensitivity compared to NAATs, espe-
cially when used with noninvasive specimens such as
vaginal swabs and urine (5-8). Emerging technologies
promise major advancements in the ﬁeld of STI
POCTs in the coming years. It is crucial to evaluate
the performance characteristics of these new tests
and their acceptability to patients and health-care
providers. The WHO facilitates access to adequate
STI POCTs within national STI programs through
comprehensive validation of new promising STI
POCTs. This WHO validation is performed in two
steps: (i) a comprehensive analytical laboratory vali-
dation and (ii) subsequent clinical validation(s) of
POCTs that show(s) appropriate results in the labo-
ratory validation.
The Xpert CT/NG and Xpert TV tests for the
GeneXpert system are NAAT-based tests that can be
used at point of care. The GeneXpert system is fully
automated, cartridge-based, and integrates sample
processing, cell lysis, puriﬁcation, nucleic acid ampli-
ﬁcation, and detection. The Xpert TV detects one
TV target (TV) and the Xpert CT/NG simultane-
ously detects CT and NG by amplifying one chromo-
somal target (CT1) for CT and two separate
chromosomal targets (NG2 and NG4) for NG. Both
NG targets need to be detected for the Xpert CT/
NG assay to return a positive NG result.
Our aim was to evaluate the analytical sensitivity
and speciﬁcity of the Xpert CT/NG and Xpert TV
tests on the GeneXpert system and, in particular,
challenge the speciﬁcity with various non-NG Neisse-
ria, non-CT Chlamydia, and non-TV Trichomonas
species as well as other closely related bacteria and
agents associated with vaginal discharge, to strictly
evaluate if particularly the Xpert CT/NG assay can
be used also for specimens from extra-genital sites
such as pharynx and rectum.
MATERIALS AND METHODS
The evaluation panel consisted of 339 samples mostly
spiked with geographically and temporally (1971–2016)
diverse isolates of NG, CT, and TV as well as non-NG
Neisseria, Moraxella, Trichomonas, Chlamydia, Candida
species, or bacterial vaginosis specimens. The panel was
assembled to include phenotypically and/or genetically
diverse strains. For NG, the well-characterized and geo-
graphically, temporally, and genetically diverse WHO refer-
ence strains (9), which include porA and cppB mutants that
have previously escaped diagnostics using other NAATs,
were included. Due to the high genetic heterogeneity of
non-NG Neisseria species and problems with cross-reactiv-
ity in several gonococcal NAATs (10), a high number of iso-
lates (n = 251) representing 15 diﬀerent non-NG Neisseria
species were tested to substantially challenge the speciﬁcity
of the Xpert CT/NG. For CT, all main genotypes, includ-
ing Lymphogranuloma venereum (LGV), and mutants, such
as the Swedish new variant of CT (nvCT), were represented.
To investigate analytical sensitivity, 10 spiked samples
each of NG, CT, and TV with known genome equivalents
(GEQs) concentrations (102–106 GEQs per reaction) based
on quantitative PCR using the C. trachomatis/N. gon-
orrhoeae/M. genitalium/T. vaginalis-multiprime-FRT PCR
kit (Ecoli s.r.o., Bratislava, Slovak Republic) on the
Rotor-Gene Q instrument (Qiagen, Hilden, Germany) and
quantiﬁed Amplirun DNA controls (Vircell, Granada,
Spain) were analyzed.
To substantially challenge the analytical speciﬁcity of the
Xpert TV test, 10 samples including four diﬀerent non-TV
Trichomonas species were tested in two concentrations
(~2.5 9 106 GEQs/test and ~1.25 9 107 GEQs/test, respec-
tively). DNA was puriﬁed using MagNA Pure Compact
Nucleic Acid Isolation Kit I (Roche Diagnostics GmbH,
Mannheim, Germany), added into a transport reagent tube
and then transferred to the reaction cartridge, according to
the manufacturer’s instructions (Cepheid, Sunnyvale, CA,
USA). To challenge the speciﬁcity of the Xpert CT/NG
assay, 10 samples, including four diﬀerent non-CT Chlamy-
dial species in two concentrations (~2.2 9 106 GEQs/test
and ~1.1 9 107 GEQs/test, respectively), were tested in the
same way as for Trichomonas. Furthermore, 254 samples,
including 15 diﬀerent non-NG Neisseria and three Morax-
ella species, were tested in high concentration as previously
described (10); two colonies were added into a transport
reagent tube and transferred to the reaction cartridge (cor-
responding to ~2 9 107 colony-forming units (CFUs)/test),
according to the manufacturer’s instructions (Cepheid, Sun-
nyvale, California, USA). In addition, 25 samples of other
causes of vaginal discharge; ﬁve each of swab samples posi-
tive for NG, CT, TV, bacterial vaginosis, and Candida spe-
cies, as well as 10 negative samples consisting of buﬀer only
were examined. Finally, to mimic human sample conditions,
10 ng/lL of K562 Human DNA high molecular weight
(Promega, Madison, WI USA) was added to each reaction/
cartridge. If any cross-reactivity was identiﬁed, the false-
positive sample was diluted to evaluate the clinical relevance
of the cross-reaction.
The APTIMA Combo 2 test and APTIMA TV test
(Hologic, Marlborough, MA, USA) were used as reference
tests and performed according to the manufacturer’s
instructions (Table 1).
RESULTS
All 10 WHO NG reference strains (9) were positive
for both NG targets (NG2 and NG4) in the Xpert
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Table 1. Positivity rate and comparison between GeneXpert and APTIMA assays for the detection of Neisseria
gonorrhoeae (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) in 339 mostly spiked samples
Bacterial species tested No. of isolates tested Positive
Xpert
CT/NG
Positive
Xpert TV
Positive
APTIMA
CT/NG
Positive
APTIMA TV
CT NG
N. gonorrhoeae WHO F 1 0 1 0 1 0
N. gonorrhoeae WHO G 1 0 1 0 1 0
N. gonorrhoeae WHO L 1 0 1 0 1 0
N. gonorrhoeae WHO M 1 0 1 0 1 0
N. gonorrhoeae WHO U 1 0 1 0 1 0
N. gonorrhoeae WHO V 1 0 1 0 1 0
N. gonorrhoeae WHO W 1 0 1 0 1 0
N. gonorrhoeae WHO X 1 0 1 0 1 0
N. gonorrhoeae WHO Y 1 0 1 0 1 0
N. gonorrhoeae WHO Z 1 0 1 0 1 0
N. gonorrhoeae positive swabs 5 0 5 0 5 0
All N. gonorrhoeae 15 0 15 0 15 0
N. animalis 1 0 0 0 0 0
N. bergeri 1 0 02 0 0 0
N. cinerea 9 0 0 0 0 0
N. elongata 3 0 0 0 0 0
N. flava 1 0 0 0 0 0
N. flavescens 90 0 0 0 0 0
N. lactamica 12 0 0 0 0 0
N. macacae 17 0 0 0 0 0
N. mucosa 18 0 0 0 0 0
N. oralis 1 0 02 0 0 0
N. perflava 62 0 0 0 0 0
N. sicca 9 0 0 0 0 0
N. subflava 6 0 0 0 0 0
N. gonorrhoeae subspecies kochii 4 0 0 0 0 0
N. meningitidis1 17 0 0 0 0 0
M. catarrhalis 1 0 0 0 0 0
M. nonliquefaciens 1 0 0 0 0 0
M. osloensis 1 0 0 0 0 0
All non-NG Neisseria or Moraxella species 254 0 0 0 0 0
C. trachomatis Ba 1 1 0 0 1 0
C. trachomatis D 1 1 0 0 1 0
C. trachomatis E 1 1 0 0 1 0
C. trachomatis F 1 1 0 0 1 0
C. trachomatis G 1 1 0 0 1 0
C. trachomatis H 1 1 0 0 1 0
C. trachomatis J 1 1 0 0 1 0
C. trachomatis K 1 1 0 0 1 0
C. trachomatis nvCT 1 1 0 0 1 0
C. trachomatis LGV (L2b) 1 1 0 0 1 0
C. trachomatis positive swabs 5 5 0 0 5 0
All C. trachomatis 15 15 0 0 15 0
C. suis (ATCC VR-1474) 2 0 0 0 0 0
C. muridarum (ATCC VR-123) 2 0 0 0 0 0
Chl. pneumoniae (ATCC VR-2282, MBC011) 4 0 0 0 0 0
Chl. psittaci (MBC013) 2 0 0 0 0 0
All non-CT Chlamydia species 10 0 0 0 0 0
T. vaginalis (incl. ATCC 30001, 50140) 10 0 0 10 0 10
T. vaginalis positive swabs 5 0 0 5 0 5
All T. vaginalis 15 0 0 15 0 15
T. aotus (ATCC 50649) 2 0 0 1 0 0
T. gallinae (ATCC 30002, 30230) 4 0 0 4 0 0
T. stableri (ATCC PRA-412) 2 0 0 2 0 0
T. tenax (ATCC30207) 2 0 0 2 0 0
All non-TV Trichomonas species 10 0 0 9 0 0
Bacterial vaginosis positive swabs 5 0 0 0 0 0
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CT/NG assay and detected at ≤102 GEQs per reac-
tion (Table 1). All 254 non-NG Neisseria species
and Moraxella species were negative in the Xpert
CT/NG assay. One (NG4) of the two NG-targets
were repeatedly detected in one N. oralis isolate
and one N. bergeri isolate; since both targets need
to be detected for a positive result, they were
reported as negative for NG by the GeneXpert
CT/NG assay software. By further dilution of the
N. oralis and N. bergeri isolates (1/10 000; to
~2 9 107 CFUs/test), both tested negative also for
the NG4 target.
All 10 CT samples were detected at ≤102 GEQs
per reaction in the Xpert CT/NG assay. No
false-positive samples were detected among the
non-CT Chlamydia species tested, C. suis (ATCC
VR-1474), C. muridarum (ATCC VR-123),
Chl. pneumoniae (ATCC VR-2282, MBC011), and
Chl. psittaci (MBC013) (Table 1).
All 10 TV samples, including the two TV ATCC
strains 30001 and 50140, were detected at ≤102
GEQs per reaction in the Xpert TV assay. In the
~1.25 9 107 GEQs/test concentration, all four non-
TV Trichomonas species examined, that is, T. tenax
(ATCC 30207), T. gallinae (ATCC 30002), T. galli-
nae (ATCC 30230), T. stableri (ATCC PRA-412),
and T. aotus (ATCC 50649) were also positive. In
the ~2.5 9 106 GEQs/test concentration, all except
T. aotus (ATCC 50649) remained positive.
No cross-reactivity was detected in the Xpert
CT/NG test or Xpert TV test when testing sam-
ples of other causes of vaginal discharge such as
bacterial vaginosis and Candida species.
The reference tests (APTIMA Combo 2 and
APTIMA TV) showed 100% sensitivity and
speciﬁcity for all tested samples (Table 1).
DISCUSSION
In the present study, the Xpert CT/NG test on
the GeneXpert system displayed a very high analyt-
ical sensitivity and speciﬁcity when substantially
challenged with a wide range of genetically diverse
NG and CT strains and various non-NG Neisseria
(including 251 isolates of 15 diﬀerent non-NG Neis-
seria species) and non-CT Chlamydia species, as
well as other closely related bacteria and agents
associated with vaginal discharge. Accordingly, we
could verify the high sensitivity and speciﬁcity of
the Xpert CT/NG test, which has been indicated
in previous studies (10-13). Our ﬁndings further
support the use of the Xpert CT/NG test for the
detection of CT and NG in also specimens from
extra-genital sites such as pharynx and rectum. We
could also verify the high sensitivity and speciﬁcity
of the Xpert TV test, which has been indicated in
two previous studies (14, 15). However, we also
show that several non-TV Trichomonas species, in
high concentrations, were also positive in the
Xpert TV test. Cross-reaction with T. tenax, a
protozoan commonly found in the oral cavity of
humans, dogs, and cats, has been identiﬁed earlier,
including by the manufacturer at levels above
1 9 102 cells/mL (16). We identiﬁed for the ﬁrst
time cross-reaction also with the avian protozoa
T. gallinae and T. stableri (17), both mainly found
in the oral–nasal cavity and infecting the respira-
tory or upper digestive tract of birds, as well as
T. aotus (18), mainly found in the intestines giving
gastroenteritis in monkeys. Nevertheless, the clinical
relevance of these cross-reactions with non-TV Tri-
chomonas species can likely be neglected because,
to our best knowledge, these species have not been
identiﬁed in urogenital samples from humans. Nev-
ertheless, additional studies addressing this issue
might be valuable.
The Xpert CT/NG and Xpert TV tests on the
GeneXpert system fulﬁll several of the WHO
ASSURED criteria (4). However, the tests do not
fulﬁll the criteria of being suﬃciently inexpensive,
rapid, and equipment-free. Nevertheless, despite the
relatively high cost per test, the signiﬁcant beneﬁts
associated with the access to POC diagnostics (in
some settings, results can be provided at the time
of the patient visit), speciﬁc detection and treatment
of etiological agent of STIs (reducing over- or
undertreatment), reduced time to treat, and
Table 1. (continued)
Bacterial species tested No. of isolates tested Positive
Xpert
CT/NG
Positive
Xpert TV
Positive
APTIMA
CT/NG
Positive
APTIMA TV
CT NG
Candida ssp. positive swabs 5 0 0 0 0 0
Negative samples 10 0 0 0 0 0
WHO, World Health Organization; LGV, lymphogranuloma venereum.
1Representing all major meningococcal clones spreading worldwide, including serogroups A, B, C, E, W, X, Y, and Z.
2Isolates displaying positivity in the NG4 target in the Xpert CT/NG test.
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opportunities for counseling and contact notiﬁca-
tion need to be taken into account in cost-eﬀective-
ness analysis. The Xpert CT/NG test and Xpert
TV test on the GeneXpert system is also relatively
rapid and produces results from the primary sample
in 1.5 and 1 h, respectively. Furthermore, the Gen-
eXpert system has been considered as suitable for
use in remote health-care settings, low-resource set-
tings, and settings with limited laboratory infras-
tructure (19), which otherwise frequently have to
rely on substantially delayed results from, for
example, a central laboratory. In a previous study
(20), it was concluded that the commercially avail-
able NAAT POCTs do not produce results quickly
enough to be provided before most patients leave
the clinic. However, the total time to treatment per
100 infected patients was estimated to decrease by
204–208 days for CT infection and 164–172 days
for gonorrhea based on the estimated reduction in
time to obtain results to one day from the current
median of three to four working days but this at
the expense of a few false-positive and false-nega-
tive results (20). The reduced time to treatment
may have signiﬁcant implications for prevention of
further disease transmission.
In conclusion, the analytical sensitivity and speci-
ﬁcity of the Xpert CT/NG and Xpert TV tests
on the GeneXpert system were high. The high ana-
lytical speciﬁcity of the Xpert CT/NG assay sup-
ports also the use of specimens from extra-genital
sites such as pharynx and rectum; however, appro-
priate clinical validations are required and the
WHO has most recently initiated a large interna-
tional clinical validation, including also specimens
from pharynx and rectum. These tests used on the
GeneXpert system are also user-friendly (for labo-
ratory staﬀ but also other health-care professionals)
and relatively rapid. Nevertheless, sensitive and
speciﬁc STI diagnostic POCTs that are more rapid
and cheaper would be valuable and the develop-
ment and validation of such assays are key priori-
ties for the management and control of curable
STIs in the future.
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